• In late June 2026, Oruka Therapeutics, Inc. was removed from several Russell value and microcap indices and simultaneously added to multiple Russell growth benchmarks, including the Russell 2000 and Russell 3000 growth indices.
• This shift effectively reclassifies Oruka Therapeutics in major index frameworks from a value- and microcap-oriented profile toward a growth-focused small-cap identity, which can materially influence how institutional investors and index-tracking funds view the company.
• Next, we will examine how this broad reclassification into growth-oriented Russell indices shapes Oruka Therapeutics’ evolving investment narrative.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

What Is Oruka Therapeutics' Investment Narrative?

For someone owning Oruka Therapeutics, the core belief is that its IL‑23 program, ORKA‑001, can translate promising early psoriasis data into a commercially relevant asset despite years of losses and no revenue so far. The main near term catalysts are still clinical and regulatory: longer term EVERLAST‑A results in the second half of 2026 and clarity on Phase 2b and partnering plans. The June shift into Russell growth indices mostly affects who holds the stock rather than the science itself, but it could amplify short term trading around news as more growth and small cap funds gain exposure while value and microcap holders rotate out. That may slightly raise the stakes around data readouts and financing, in a business where ongoing cash burn, future dilution and clinical risk remain front and center.

However, one risk around future funding and dilution is easy to overlook until it matters. In light of our recent valuation report, it seems possible that Oruka Therapeutics is trading beyond its estimated value.

Exploring Other Perspectives

Two Simply Wall St Community fair value views span roughly US$14 to US$145 per share, underlining how differently people see Oruka’s potential, especially with index reclassification now sharpening focus on clinical milestones and funding risk.

Explore 2 other fair value estimates on Oruka Therapeutics - why the stock might be worth as much as 64% more than the current price!

Form Your Own Verdict

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Oruka Therapeutics research is our analysis highlighting 4 important warning signs that could impact your investment decision.
• Our free Oruka Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oruka Therapeutics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.